Prevalence and incidence of peritoneal dialysis (PD) in Asia are both increasing, but the increase is not homogenous. In some countries and regions, PD is not used as one of the standard therapeutic modalities, because of either insufficient medico-economic infrastructure or a lack of clinical experience and knowledge—or sometime both. In the present article, we would like to introduce a little “Asian heat” with regard to PD utilization and academic and scientific contributions to the PD community in the world.
GrassmannAGiobergeSMoellerSBrownG.ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant2005; 20:2587–93.
2.
LinTCKaoMTLaiMNHaungCC. Mortality difference by dialysis modality among new ESRD patients with and without diabetes mellitus. Dial Transplant2006; 35:234–44.
3.
WangAYM. The John F. Maher Award Recipient Lecture 2006. The “heart” of peritoneal dialysis: residual renal function. Perit Dial Int2007; 27(Suppl 2):S228–32.
4.
WangAYLamCWWangMWooJChanIHLuiSF. Circulating soluble vascular cell adhesion molecule 1: relationships with residual renal function, cardiac hypertrophy, and outcome of peritoneal dialysis patients. Am J Kidney Dis2005; 45:715–29.
5.
ChengLTChenWTangWWangT.Residual renal function and volume control in peritoneal dialysis patients. Nephron Clin Pract2006; 104:c47–54.
6.
WangAYWooJWangMSeaMMSandersonJELuiSF. Important differentiation of factors that predict outcome in peritoneal dialysis patients with different degrees of residual renal function. Nephrol Dial Transplant2005; 20:396–403.
7.
KawanishiHHashimotoYNakamotoHNakayamaMTranæusA.Combination therapy with peritoneal dialysis and hemodialysis. Perit Dial Int2006; 26:150–4.
8.
KawanishiHMoriishiM.Epidemiology of encapsulating peritoneal sclerosis in Japan. Perit Dial Int2005; 25(Suppl 4):S14–18.
9.
FierenMWBetjesMGKorteMRBoerWH. Posttransplant encapsulating peritoneal sclerosis: a worrying new trend?Perit Dial Int2007; 27:619–24.
10.
SummersAMClancyMJSyedFHarwoodNBrenchleyPEAugustineT. Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure. Kidney Int2005; 68:2381–8.
11.
EltoumMAWrightSAtchleyJMasonJC. Four consecutive cases of peritoneal dialysis-related encapsulating peritoneal sclerosis treated successfully with tamoxifen. Perit Dial Int2006; 26:203–6.
12.
KawaguchiYSaitoAKawanishiHNakayamaMMiyazakiMNakamotoH. Recommendations on the management of encapsulating peritoneal sclerosis in Japan, 2005: diagnosis, predictive markers, treatment, and preventive measures. Perit Dial Int2005; 25(Suppl 4):S83–95.
LeeHYParkHCSeoBJDoJYYunSRSongHY. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Dial Int2005; 25:248–55.
